Evoke Pharma (EVOK)

Evoke Pharma is an advanced-clinical stage pharmaceutical company focused on discovering, development and commercialization of EVK-001 as a potential treatment of diabetic gastroparesis.  EVK-001 is an intranasally delivered metoclopramide for the purpose of treating gastroparesis by circumventing the shortcoming – reduced treatment impact caused by unpredictable drug absorption – of the current oral metoclopramide-based treatment. The company expects to commence a Phase III pivotal study in 2Q14 and expect to report top-line results in late 2H15.  As such, EVK-001 could potential reach market in late 2016.

Published Reports

EVOK-2018-11-14-3Q18
EVOK-2018-08-16-PDUFA date of 04-01-2019
EVOK-2018-08-10-2Q18
EVOK-2018-05-14-1Q18
EVOK-2018-03-08-Gimoti NDA Filing scheduled
EVOK-2018-02-15-New PK information
EVOK-2017-11-15-3Q17
EVOK-2017-10-31-More details regarding PK trial
EVOK-2017-10-24-PK outcome positive
EVOK-2017-08-15-2Q17 rev
EVOK-2017-05-16-1Q17 rev
EVOK-2017-05-10-DDW Poster rev
EVOK-2017-04-04-PK trial rev
EVOK-2017-03-16-4Q16 rev3
EVOK-2017-01-30-Upgrade to Buy rev2
EVOK-2017-01-04-Additional Gimoti P3 data (1) rev
EVOK-2016-12-16-Positive FDA discussions on Gimoti filing rev
evok-2016-11-11-3q16-revb-2
EVOK-2016-07-07-Inventiv agreement (1) rev
EVOK-2016-06-30-KOL call rev
EVOK-2016-05-12-1Q16 rev2
EVOK-2016-05-03-EVK-001 Phase III top line in 3Q16 rev 2
EVOK-2016-04-25-EVK-001 patient enrollment completed rev
EVOK-2016-03-11-4Q15
EVOK-2016-03-1-METO IN-003 Update rev2
EVOK-2015-11-13-3Q15 rev
EVOK-2015-09-15-FDA draft guidance
EVOK-2015-08-14-2Q15
EVOK-2015-03-05-4Q14
EVOK-2014-08-14-2Q14
EVOK-2015-08-19-Pediatric study plan accepted rev (4)
EVOK-2015-05-15-1Q15 rev
EVOK-2015-04-14-Manufacturing milestone rev
EVOK-2054-02-03-P3 to complete by 4Q15 rev
EVOK-2014-11-14-3Q14 rev
EVOK-2014-05-14-1Q14 rev
EVOK-2014-04-22-P3 started
EVOK-initiation-2014-04-22-Final